One-year treatment with standard and sustained-release levodopa: Appropriate long-term treatment of restless legs syndrome?
Identifieur interne : 002372 ( PascalFrancis/Corpus ); précédent : 002371; suivant : 002373One-year treatment with standard and sustained-release levodopa: Appropriate long-term treatment of restless legs syndrome?
Auteurs : Claudia Trenkwalder ; Victor Collado Seidel ; Jörg Kazenwadel ; Thomas C. Wetter ; Wolfgang Oertel ; Roland Selzer ; Ralf KohnenSource :
- Movement disorders [ 0885-3185 ] ; 2003.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
To investigate the long-term efficacy and safety of sustained-release (SR) in combination with regular-release (RR) levodopa/benserazide in the treatment of restless legs syndrome (RLS), an open-label, prospective, extension study of a preceding double-blind crossover trial was performed for 12 months. Twenty-three severely disturbed RLS patients (7 men, 16 women) received a combination of RR and SR levodopa. Patients were treated on average for 10 months with a mean daily dose of 203 ± 101 mg of RR and of 185 ± 93 mg of SR levodopa. The mean daily total dose was 388 ± 162 mg levodopa. Efficacy was documented using patient's rating scales, sleep diaries, and investigator's global ratings with the Clinical Global Impressions (CGI). Ten of 23 patients completed the 1-year extension. Between baseline of the crossover trial and endpoint of the extension study (last-observation-carried-forward method, intention-to-treat population), quality of sleep improved (+3.5 ± 1.9, 7-point scale), sleep latency was shortened (-131 ± 152 minutes), and total sleep time lengthened (+ 190 ± 136 minutes). Severity of RLS at time of falling asleep (-6.5 ± 3.4, 11-point scale) and during the night (-6.0 ± 3.5) was markedly lower at the end of the extension but severity of RLS during the day (+1.9 ± 5.0) slightly increased. Of 13 dropouts, 8 patients discontinued therapy because of worsening RLS during the day. This trial shows that long-term treatment with the combination of RR and SR levodopa/benserazide in RLS patients with late-night problems was efficacious and not limited by tolerability problems in 40% of patients, whereas in the majority of patients, aggravating daytime problems required termination of the levodopa therapy within the 1-year treatment period.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
|
|---|
Format Inist (serveur)
| NO : | PASCAL 04-0095339 INIST |
|---|---|
| ET : | One-year treatment with standard and sustained-release levodopa: Appropriate long-term treatment of restless legs syndrome? |
| AU : | TRENKWALDER (Claudia); SEIDEL (Victor Collado); KAZENWADEL (Jörg); WETTER (Thomas C.); OERTEL (Wolfgang); SELZER (Roland); KOHNEN (Ralf) |
| AF : | Max Planck Institute of Psychiatry, Munich and Department of Clinical Neurophysiology/Goettingen/Allemagne (1 aut., 2 aut., 4 aut.); Hoffmann-La Roche AG/Basel/Suisse (3 aut.); Department of Neurology, Philipps University of Marburg/Marburg/Allemagne (5 aut.); Hoffmann-La Roche AG/Grenzach/Allemagne (6 aut.); IMEREM Institute for Medical Research Management and Biometrics GmbH/Nuernberg/Allemagne (7 aut.) |
| DT : | Publication en série; Courte communication, note brève; Niveau analytique |
| SO : | Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2003; Vol. 18; No. 10; Pp. 1184-1189; Bibl. 19 ref. |
| LA : | Anglais |
| EA : | To investigate the long-term efficacy and safety of sustained-release (SR) in combination with regular-release (RR) levodopa/benserazide in the treatment of restless legs syndrome (RLS), an open-label, prospective, extension study of a preceding double-blind crossover trial was performed for 12 months. Twenty-three severely disturbed RLS patients (7 men, 16 women) received a combination of RR and SR levodopa. Patients were treated on average for 10 months with a mean daily dose of 203 ± 101 mg of RR and of 185 ± 93 mg of SR levodopa. The mean daily total dose was 388 ± 162 mg levodopa. Efficacy was documented using patient's rating scales, sleep diaries, and investigator's global ratings with the Clinical Global Impressions (CGI). Ten of 23 patients completed the 1-year extension. Between baseline of the crossover trial and endpoint of the extension study (last-observation-carried-forward method, intention-to-treat population), quality of sleep improved (+3.5 ± 1.9, 7-point scale), sleep latency was shortened (-131 ± 152 minutes), and total sleep time lengthened (+ 190 ± 136 minutes). Severity of RLS at time of falling asleep (-6.5 ± 3.4, 11-point scale) and during the night (-6.0 ± 3.5) was markedly lower at the end of the extension but severity of RLS during the day (+1.9 ± 5.0) slightly increased. Of 13 dropouts, 8 patients discontinued therapy because of worsening RLS during the day. This trial shows that long-term treatment with the combination of RR and SR levodopa/benserazide in RLS patients with late-night problems was efficacious and not limited by tolerability problems in 40% of patients, whereas in the majority of patients, aggravating daytime problems required termination of the levodopa therapy within the 1-year treatment period. |
| CC : | 002B02B06 |
| FD : | Impatience membre inférieur syndrome; Lévodopa; Chimiothérapie; Association médicamenteuse; Bensérazide; Forme libération contrôlée; Long terme; Etude double insu; Essai croisé; Toxicité; Traitement; Protocole thérapeutique; Pronostic; Homme |
| FG : | Système nerveux pathologie; Trouble neurologique; Trouble sensibilité; Antiparkinsonien; Decarboxylase; Carboxy-lyases; Carbon-carbon lyases; Lyases; Enzyme; Inhibiteur enzyme; Forme pharmaceutique |
| ED : | Restless legs syndrome; Levodopa; Chemotherapy; Drug combination; Benserazide; Controlled release form; Long term; Double blind study; Crossover study; Toxicity; Treatment; Therapeutic protocol; Prognosis; Human |
| EG : | Nervous system diseases; Neurological disorder; Sensitivity disorder; Antiparkinson agent; Decarboxylase; Carboxy-lyases; Carbon-carbon lyases; Lyases; Enzyme; Enzyme inhibitor; Dosage form |
| SD : | Acroparestesia nocturna; Levodopa; Quimioterapia; Asociación medicamentosa; Benserazida; Forma liberación controlada; Largo plazo; Estudio doble ciego; Ensayo cruzado; Toxicidad; Tratamiento; Protocolo terapéutico; Pronóstico; Hombre |
| LO : | INIST-20953.354000113383090140 |
| ID : | 04-0095339 |
Links to Exploration step
Pascal:04-0095339Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">One-year treatment with standard and sustained-release levodopa: Appropriate long-term treatment of restless legs syndrome?</title><author><name sortKey="Trenkwalder, Claudia" sort="Trenkwalder, Claudia" uniqKey="Trenkwalder C" first="Claudia" last="Trenkwalder">Claudia Trenkwalder</name><affiliation><inist:fA14 i1="01"><s1>Max Planck Institute of Psychiatry, Munich and Department of Clinical Neurophysiology</s1><s2>Goettingen</s2><s3>DEU</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Seidel, Victor Collado" sort="Seidel, Victor Collado" uniqKey="Seidel V" first="Victor Collado" last="Seidel">Victor Collado Seidel</name><affiliation><inist:fA14 i1="01"><s1>Max Planck Institute of Psychiatry, Munich and Department of Clinical Neurophysiology</s1><s2>Goettingen</s2><s3>DEU</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Kazenwadel, Jorg" sort="Kazenwadel, Jorg" uniqKey="Kazenwadel J" first="Jörg" last="Kazenwadel">Jörg Kazenwadel</name><affiliation><inist:fA14 i1="02"><s1>Hoffmann-La Roche AG</s1><s2>Basel</s2><s3>CHE</s3><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Wetter, Thomas C" sort="Wetter, Thomas C" uniqKey="Wetter T" first="Thomas C." last="Wetter">Thomas C. Wetter</name><affiliation><inist:fA14 i1="01"><s1>Max Planck Institute of Psychiatry, Munich and Department of Clinical Neurophysiology</s1><s2>Goettingen</s2><s3>DEU</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Oertel, Wolfgang" sort="Oertel, Wolfgang" uniqKey="Oertel W" first="Wolfgang" last="Oertel">Wolfgang Oertel</name><affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Philipps University of Marburg</s1><s2>Marburg</s2><s3>DEU</s3><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Selzer, Roland" sort="Selzer, Roland" uniqKey="Selzer R" first="Roland" last="Selzer">Roland Selzer</name><affiliation><inist:fA14 i1="04"><s1>Hoffmann-La Roche AG</s1><s2>Grenzach</s2><s3>DEU</s3><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Kohnen, Ralf" sort="Kohnen, Ralf" uniqKey="Kohnen R" first="Ralf" last="Kohnen">Ralf Kohnen</name><affiliation><inist:fA14 i1="05"><s1>IMEREM Institute for Medical Research Management and Biometrics GmbH</s1><s2>Nuernberg</s2><s3>DEU</s3><sZ>7 aut.</sZ></inist:fA14></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">04-0095339</idno><date when="2003">2003</date><idno type="stanalyst">PASCAL 04-0095339 INIST</idno><idno type="RBID">Pascal:04-0095339</idno><idno type="wicri:Area/PascalFrancis/Corpus">002372</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">One-year treatment with standard and sustained-release levodopa: Appropriate long-term treatment of restless legs syndrome?</title><author><name sortKey="Trenkwalder, Claudia" sort="Trenkwalder, Claudia" uniqKey="Trenkwalder C" first="Claudia" last="Trenkwalder">Claudia Trenkwalder</name><affiliation><inist:fA14 i1="01"><s1>Max Planck Institute of Psychiatry, Munich and Department of Clinical Neurophysiology</s1><s2>Goettingen</s2><s3>DEU</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Seidel, Victor Collado" sort="Seidel, Victor Collado" uniqKey="Seidel V" first="Victor Collado" last="Seidel">Victor Collado Seidel</name><affiliation><inist:fA14 i1="01"><s1>Max Planck Institute of Psychiatry, Munich and Department of Clinical Neurophysiology</s1><s2>Goettingen</s2><s3>DEU</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Kazenwadel, Jorg" sort="Kazenwadel, Jorg" uniqKey="Kazenwadel J" first="Jörg" last="Kazenwadel">Jörg Kazenwadel</name><affiliation><inist:fA14 i1="02"><s1>Hoffmann-La Roche AG</s1><s2>Basel</s2><s3>CHE</s3><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Wetter, Thomas C" sort="Wetter, Thomas C" uniqKey="Wetter T" first="Thomas C." last="Wetter">Thomas C. Wetter</name><affiliation><inist:fA14 i1="01"><s1>Max Planck Institute of Psychiatry, Munich and Department of Clinical Neurophysiology</s1><s2>Goettingen</s2><s3>DEU</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Oertel, Wolfgang" sort="Oertel, Wolfgang" uniqKey="Oertel W" first="Wolfgang" last="Oertel">Wolfgang Oertel</name><affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Philipps University of Marburg</s1><s2>Marburg</s2><s3>DEU</s3><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Selzer, Roland" sort="Selzer, Roland" uniqKey="Selzer R" first="Roland" last="Selzer">Roland Selzer</name><affiliation><inist:fA14 i1="04"><s1>Hoffmann-La Roche AG</s1><s2>Grenzach</s2><s3>DEU</s3><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Kohnen, Ralf" sort="Kohnen, Ralf" uniqKey="Kohnen R" first="Ralf" last="Kohnen">Ralf Kohnen</name><affiliation><inist:fA14 i1="05"><s1>IMEREM Institute for Medical Research Management and Biometrics GmbH</s1><s2>Nuernberg</s2><s3>DEU</s3><sZ>7 aut.</sZ></inist:fA14></affiliation></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="2003">2003</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Benserazide</term><term>Chemotherapy</term><term>Controlled release form</term><term>Crossover study</term><term>Double blind study</term><term>Drug combination</term><term>Human</term><term>Levodopa</term><term>Long term</term><term>Prognosis</term><term>Restless legs syndrome</term><term>Therapeutic protocol</term><term>Toxicity</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Impatience membre inférieur syndrome</term><term>Lévodopa</term><term>Chimiothérapie</term><term>Association médicamenteuse</term><term>Bensérazide</term><term>Forme libération contrôlée</term><term>Long terme</term><term>Etude double insu</term><term>Essai croisé</term><term>Toxicité</term><term>Traitement</term><term>Protocole thérapeutique</term><term>Pronostic</term><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To investigate the long-term efficacy and safety of sustained-release (SR) in combination with regular-release (RR) levodopa/benserazide in the treatment of restless legs syndrome (RLS), an open-label, prospective, extension study of a preceding double-blind crossover trial was performed for 12 months. Twenty-three severely disturbed RLS patients (7 men, 16 women) received a combination of RR and SR levodopa. Patients were treated on average for 10 months with a mean daily dose of 203 ± 101 mg of RR and of 185 ± 93 mg of SR levodopa. The mean daily total dose was 388 ± 162 mg levodopa. Efficacy was documented using patient's rating scales, sleep diaries, and investigator's global ratings with the Clinical Global Impressions (CGI). Ten of 23 patients completed the 1-year extension. Between baseline of the crossover trial and endpoint of the extension study (last-observation-carried-forward method, intention-to-treat population), quality of sleep improved (+3.5 ± 1.9, 7-point scale), sleep latency was shortened (-131 ± 152 minutes), and total sleep time lengthened (+ 190 ± 136 minutes). Severity of RLS at time of falling asleep (-6.5 ± 3.4, 11-point scale) and during the night (-6.0 ± 3.5) was markedly lower at the end of the extension but severity of RLS during the day (+1.9 ± 5.0) slightly increased. Of 13 dropouts, 8 patients discontinued therapy because of worsening RLS during the day. This trial shows that long-term treatment with the combination of RR and SR levodopa/benserazide in RLS patients with late-night problems was efficacious and not limited by tolerability problems in 40% of patients, whereas in the majority of patients, aggravating daytime problems required termination of the levodopa therapy within the 1-year treatment period.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0></fA01><fA03 i2="1"><s0>Mov. disord.</s0></fA03><fA05><s2>18</s2></fA05><fA06><s2>10</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>One-year treatment with standard and sustained-release levodopa: Appropriate long-term treatment of restless legs syndrome?</s1></fA08><fA11 i1="01" i2="1"><s1>TRENKWALDER (Claudia)</s1></fA11><fA11 i1="02" i2="1"><s1>SEIDEL (Victor Collado)</s1></fA11><fA11 i1="03" i2="1"><s1>KAZENWADEL (Jörg)</s1></fA11><fA11 i1="04" i2="1"><s1>WETTER (Thomas C.)</s1></fA11><fA11 i1="05" i2="1"><s1>OERTEL (Wolfgang)</s1></fA11><fA11 i1="06" i2="1"><s1>SELZER (Roland)</s1></fA11><fA11 i1="07" i2="1"><s1>KOHNEN (Ralf)</s1></fA11><fA14 i1="01"><s1>Max Planck Institute of Psychiatry, Munich and Department of Clinical Neurophysiology</s1><s2>Goettingen</s2><s3>DEU</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ></fA14><fA14 i1="02"><s1>Hoffmann-La Roche AG</s1><s2>Basel</s2><s3>CHE</s3><sZ>3 aut.</sZ></fA14><fA14 i1="03"><s1>Department of Neurology, Philipps University of Marburg</s1><s2>Marburg</s2><s3>DEU</s3><sZ>5 aut.</sZ></fA14><fA14 i1="04"><s1>Hoffmann-La Roche AG</s1><s2>Grenzach</s2><s3>DEU</s3><sZ>6 aut.</sZ></fA14><fA14 i1="05"><s1>IMEREM Institute for Medical Research Management and Biometrics GmbH</s1><s2>Nuernberg</s2><s3>DEU</s3><sZ>7 aut.</sZ></fA14><fA20><s1>1184-1189</s1></fA20><fA21><s1>2003</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>20953</s2><s5>354000113383090140</s5></fA43><fA44><s0>0000</s0><s1>© 2004 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>19 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>04-0095339</s0></fA47><fA60><s1>P</s1><s3>CC</s3></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Movement disorders</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>To investigate the long-term efficacy and safety of sustained-release (SR) in combination with regular-release (RR) levodopa/benserazide in the treatment of restless legs syndrome (RLS), an open-label, prospective, extension study of a preceding double-blind crossover trial was performed for 12 months. Twenty-three severely disturbed RLS patients (7 men, 16 women) received a combination of RR and SR levodopa. Patients were treated on average for 10 months with a mean daily dose of 203 ± 101 mg of RR and of 185 ± 93 mg of SR levodopa. The mean daily total dose was 388 ± 162 mg levodopa. Efficacy was documented using patient's rating scales, sleep diaries, and investigator's global ratings with the Clinical Global Impressions (CGI). Ten of 23 patients completed the 1-year extension. Between baseline of the crossover trial and endpoint of the extension study (last-observation-carried-forward method, intention-to-treat population), quality of sleep improved (+3.5 ± 1.9, 7-point scale), sleep latency was shortened (-131 ± 152 minutes), and total sleep time lengthened (+ 190 ± 136 minutes). Severity of RLS at time of falling asleep (-6.5 ± 3.4, 11-point scale) and during the night (-6.0 ± 3.5) was markedly lower at the end of the extension but severity of RLS during the day (+1.9 ± 5.0) slightly increased. Of 13 dropouts, 8 patients discontinued therapy because of worsening RLS during the day. This trial shows that long-term treatment with the combination of RR and SR levodopa/benserazide in RLS patients with late-night problems was efficacious and not limited by tolerability problems in 40% of patients, whereas in the majority of patients, aggravating daytime problems required termination of the levodopa therapy within the 1-year treatment period.</s0></fC01><fC02 i1="01" i2="X"><s0>002B02B06</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Impatience membre inférieur syndrome</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Restless legs syndrome</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Acroparestesia nocturna</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Lévodopa</s0><s2>NK</s2><s2>FR</s2><s5>04</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Levodopa</s0><s2>NK</s2><s2>FR</s2><s5>04</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Levodopa</s0><s2>NK</s2><s2>FR</s2><s5>04</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Chimiothérapie</s0><s5>05</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Chemotherapy</s0><s5>05</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Quimioterapia</s0><s5>05</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Association médicamenteuse</s0><s5>06</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Drug combination</s0><s5>06</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Asociación medicamentosa</s0><s5>06</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Bensérazide</s0><s2>NK</s2><s2>FR</s2><s5>07</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Benserazide</s0><s2>NK</s2><s2>FR</s2><s5>07</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Benserazida</s0><s2>NK</s2><s2>FR</s2><s5>07</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Forme libération contrôlée</s0><s5>10</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Controlled release form</s0><s5>10</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Forma liberación controlada</s0><s5>10</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Long terme</s0><s5>11</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Long term</s0><s5>11</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Largo plazo</s0><s5>11</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Etude double insu</s0><s5>13</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Double blind study</s0><s5>13</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Estudio doble ciego</s0><s5>13</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Essai croisé</s0><s5>14</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Crossover study</s0><s5>14</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Ensayo cruzado</s0><s5>14</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Toxicité</s0><s5>16</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Toxicity</s0><s5>16</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Toxicidad</s0><s5>16</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Traitement</s0><s5>17</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>Treatment</s0><s5>17</s5></fC03><fC03 i1="11" i2="X" l="SPA"><s0>Tratamiento</s0><s5>17</s5></fC03><fC03 i1="12" i2="X" l="FRE"><s0>Protocole thérapeutique</s0><s5>18</s5></fC03><fC03 i1="12" i2="X" l="ENG"><s0>Therapeutic protocol</s0><s5>18</s5></fC03><fC03 i1="12" i2="X" l="SPA"><s0>Protocolo terapéutico</s0><s5>18</s5></fC03><fC03 i1="13" i2="X" l="FRE"><s0>Pronostic</s0><s5>19</s5></fC03><fC03 i1="13" i2="X" l="ENG"><s0>Prognosis</s0><s5>19</s5></fC03><fC03 i1="13" i2="X" l="SPA"><s0>Pronóstico</s0><s5>19</s5></fC03><fC03 i1="14" i2="X" l="FRE"><s0>Homme</s0><s5>20</s5></fC03><fC03 i1="14" i2="X" l="ENG"><s0>Human</s0><s5>20</s5></fC03><fC03 i1="14" i2="X" l="SPA"><s0>Hombre</s0><s5>20</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Trouble neurologique</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Neurological disorder</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Trastorno neurológico</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Trouble sensibilité</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Sensitivity disorder</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Trastorno sensibilidad</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Antiparkinsonien</s0><s5>45</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Antiparkinson agent</s0><s5>45</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Antiparkinsoniano</s0><s5>45</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Decarboxylase</s0><s2>FE</s2><s5>53</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Decarboxylase</s0><s2>FE</s2><s5>53</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Decarboxylase</s0><s2>FE</s2><s5>53</s5></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Carboxy-lyases</s0><s2>FE</s2></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Carboxy-lyases</s0><s2>FE</s2></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Carboxy-lyases</s0><s2>FE</s2></fC07><fC07 i1="07" i2="X" l="FRE"><s0>Carbon-carbon lyases</s0><s2>FE</s2></fC07><fC07 i1="07" i2="X" l="ENG"><s0>Carbon-carbon lyases</s0><s2>FE</s2></fC07><fC07 i1="07" i2="X" l="SPA"><s0>Carbon-carbon lyases</s0><s2>FE</s2></fC07><fC07 i1="08" i2="X" l="FRE"><s0>Lyases</s0><s2>FE</s2></fC07><fC07 i1="08" i2="X" l="ENG"><s0>Lyases</s0><s2>FE</s2></fC07><fC07 i1="08" i2="X" l="SPA"><s0>Lyases</s0><s2>FE</s2></fC07><fC07 i1="09" i2="X" l="FRE"><s0>Enzyme</s0><s2>FE</s2></fC07><fC07 i1="09" i2="X" l="ENG"><s0>Enzyme</s0><s2>FE</s2></fC07><fC07 i1="09" i2="X" l="SPA"><s0>Enzima</s0><s2>FE</s2></fC07><fC07 i1="10" i2="X" l="FRE"><s0>Inhibiteur enzyme</s0><s5>54</s5></fC07><fC07 i1="10" i2="X" l="ENG"><s0>Enzyme inhibitor</s0><s5>54</s5></fC07><fC07 i1="10" i2="X" l="SPA"><s0>Inhibidor enzima</s0><s5>54</s5></fC07><fC07 i1="11" i2="X" l="FRE"><s0>Forme pharmaceutique</s0><s5>61</s5></fC07><fC07 i1="11" i2="X" l="ENG"><s0>Dosage form</s0><s5>61</s5></fC07><fC07 i1="11" i2="X" l="SPA"><s0>Forma farmacéutica</s0><s5>61</s5></fC07><fN21><s1>061</s1></fN21><fN82><s1>PSI</s1></fN82></pA></standard><server><NO>PASCAL 04-0095339 INIST</NO><ET>One-year treatment with standard and sustained-release levodopa: Appropriate long-term treatment of restless legs syndrome?</ET><AU>TRENKWALDER (Claudia); SEIDEL (Victor Collado); KAZENWADEL (Jörg); WETTER (Thomas C.); OERTEL (Wolfgang); SELZER (Roland); KOHNEN (Ralf)</AU><AF>Max Planck Institute of Psychiatry, Munich and Department of Clinical Neurophysiology/Goettingen/Allemagne (1 aut., 2 aut., 4 aut.); Hoffmann-La Roche AG/Basel/Suisse (3 aut.); Department of Neurology, Philipps University of Marburg/Marburg/Allemagne (5 aut.); Hoffmann-La Roche AG/Grenzach/Allemagne (6 aut.); IMEREM Institute for Medical Research Management and Biometrics GmbH/Nuernberg/Allemagne (7 aut.)</AF><DT>Publication en série; Courte communication, note brève; Niveau analytique</DT><SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2003; Vol. 18; No. 10; Pp. 1184-1189; Bibl. 19 ref.</SO><LA>Anglais</LA><EA>To investigate the long-term efficacy and safety of sustained-release (SR) in combination with regular-release (RR) levodopa/benserazide in the treatment of restless legs syndrome (RLS), an open-label, prospective, extension study of a preceding double-blind crossover trial was performed for 12 months. Twenty-three severely disturbed RLS patients (7 men, 16 women) received a combination of RR and SR levodopa. Patients were treated on average for 10 months with a mean daily dose of 203 ± 101 mg of RR and of 185 ± 93 mg of SR levodopa. The mean daily total dose was 388 ± 162 mg levodopa. Efficacy was documented using patient's rating scales, sleep diaries, and investigator's global ratings with the Clinical Global Impressions (CGI). Ten of 23 patients completed the 1-year extension. Between baseline of the crossover trial and endpoint of the extension study (last-observation-carried-forward method, intention-to-treat population), quality of sleep improved (+3.5 ± 1.9, 7-point scale), sleep latency was shortened (-131 ± 152 minutes), and total sleep time lengthened (+ 190 ± 136 minutes). Severity of RLS at time of falling asleep (-6.5 ± 3.4, 11-point scale) and during the night (-6.0 ± 3.5) was markedly lower at the end of the extension but severity of RLS during the day (+1.9 ± 5.0) slightly increased. Of 13 dropouts, 8 patients discontinued therapy because of worsening RLS during the day. This trial shows that long-term treatment with the combination of RR and SR levodopa/benserazide in RLS patients with late-night problems was efficacious and not limited by tolerability problems in 40% of patients, whereas in the majority of patients, aggravating daytime problems required termination of the levodopa therapy within the 1-year treatment period.</EA><CC>002B02B06</CC><FD>Impatience membre inférieur syndrome; Lévodopa; Chimiothérapie; Association médicamenteuse; Bensérazide; Forme libération contrôlée; Long terme; Etude double insu; Essai croisé; Toxicité; Traitement; Protocole thérapeutique; Pronostic; Homme</FD><FG>Système nerveux pathologie; Trouble neurologique; Trouble sensibilité; Antiparkinsonien; Decarboxylase; Carboxy-lyases; Carbon-carbon lyases; Lyases; Enzyme; Inhibiteur enzyme; Forme pharmaceutique</FG><ED>Restless legs syndrome; Levodopa; Chemotherapy; Drug combination; Benserazide; Controlled release form; Long term; Double blind study; Crossover study; Toxicity; Treatment; Therapeutic protocol; Prognosis; Human</ED><EG>Nervous system diseases; Neurological disorder; Sensitivity disorder; Antiparkinson agent; Decarboxylase; Carboxy-lyases; Carbon-carbon lyases; Lyases; Enzyme; Enzyme inhibitor; Dosage form</EG><SD>Acroparestesia nocturna; Levodopa; Quimioterapia; Asociación medicamentosa; Benserazida; Forma liberación controlada; Largo plazo; Estudio doble ciego; Ensayo cruzado; Toxicidad; Tratamiento; Protocolo terapéutico; Pronóstico; Hombre</SD><LO>INIST-20953.354000113383090140</LO><ID>04-0095339</ID></server></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002372 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002372 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:04-0095339
|texte= One-year treatment with standard and sustained-release levodopa: Appropriate long-term treatment of restless legs syndrome?
}}
| This area was generated with Dilib version V0.6.23. |  |